|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4,272.05 - 4,405.00|
|52 Week Range||3,654.00 - 5,077.00|
|Beta (5Y Monthly)||0.25|
|PE Ratio (TTM)||24.26|
|Earnings Date||May 10, 2018 - May 14, 2018|
|Forward Dividend & Yield||30.00 (0.72%)|
|Ex-Dividend Date||Jul 12, 2022|
|1y Target Est||2,587.45|
Subscribe to Yahoo Finance Plus to view Fair Value for DRREDDY.NS
HYDERABAD, India & PRINCETON, N.J., September 07, 2022--Dr. Reddy’s Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.